StreetAlpha.app
Home › Stocks › LYEL

Lyell Immunopharma, Inc. (LYEL)

Healthcare
Members
LATEST PRICE

Lyell Immunopharma develops engineered immune cell therapies for patients with cancer. LYEL reports earnings on Tue, Nov 10, 2026.

Prices, price targets and earnings estimates for LYEL are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is LYEL in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 10
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated LYEL in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for LYELThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
StifelInitiated
Aug 6Buy
B. Riley SecuritiesInitiated
Jul 22Buy
HC Wainwright & Co.Reiterated
Jun 9Buy
NeedhamReiterated
Jun 8Buy
HC Wainwright & Co.Reiterated
Jun 3Buy
DateFirmActionRatingPrice target
Aug 6StifelInitiatedBuy
Jul 22B. Riley SecuritiesInitiatedBuy
Jun 9HC Wainwright & Co.ReiteratedBuy
Jun 8NeedhamReiteratedBuy
Jun 3HC Wainwright & Co.ReiteratedBuy
Loading…

Seasonality

How LYEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LYEL in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LYEL is in one of them and how their past LYEL trades turned out.

See how it works→ View all auto pilots→
LYEL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LYEL in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Lyell Immunopharma

Lyell Immunopharma is a clinical stage biotechnology company that develops cell therapies for patients with cancer. It takes immune cells from each patient and engineers them to better find and destroy cancer cells. Its lead candidate, rondecabtagene autoleucel, is being studied in patients with large B cell lymphoma, and the company is also developing LYL273 for advanced colorectal cancer. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA
Summary based on the company’s 2026 annual report (10-K) ↗